Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:27 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Hansa Biopharma - Update ahead of 2023 – Gradual progress ahead

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Hansa Biopharma - Update ahead of 2023 – Gradual progress ahead

2023-02-10 11:12:00

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a slight negative revision after the recent Q4 result, and the most significant change is the number of shares relating to funding protecting the equity levels. Our Base Case is SEK 170 (410) with a Bull Case of SEK 400 (600) and a Bear Case of SEK 45 (175).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/